
Perjeta Improves Survival in HER2-Positive Breast Cancer Patients
The monoclonal antibody extended survival by nearly 16 months compared to those in the control cohort.
In Madrid today, researchers presented new findings on the effectiveness of Perjeta (
The international randomized
Over half of the women with Her2+ metastatic breast cancer who received all three drugs (Perjeta, Herceptin and chemotherapy) lived for over 4.5 years on the study. This result confirms and bolsters earlier results of CLEOPATRA study, published in the
Read the report on Forbes:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.